Zeneca Zomig
Executive Summary
Zeneca journal ad comparing migraine therapy zolmitriptan to Glaxo Wellcome's Imitrex (sumatriptan) is in breach of the Association of British Pharmaceutical Industry's Code of Practice, the Prescription Medicines Code of Practice Authority panel finds in its most recent report on advertising reviews. The ad is headed by the statement "WOW!" followed by, "In migraine, Zomig 2.5 mg is significantly more effective than sumatriptan 50 mg for headache response at two and four hours." The data show that Zomig and Imitrex response rates at two and four hours were 67% vs. 64% and 83% vs. 81%, respectively. The panel accepted that Zomig data showed a statistically significant greater response than Imitrex, which "might be clinically relevant." However, use of word "WOW" implies that readers would notice "large clinical difference" between Zomig and Imitrex
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth